KENNETH MCCLAIN to Treatment Outcome
This is a "connection" page, showing publications KENNETH MCCLAIN has written about Treatment Outcome.
Connection Strength
0.162
-
Optimal therapy for adults with Langerhans cell histiocytosis bone lesions. PLoS One. 2012; 7(8):e43257.
Score: 0.032
-
A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer. 2007 Jan; 48(1):44-9.
Score: 0.021
-
Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May; 204(5):1888-1893.
Score: 0.018
-
Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May; 204(5):1882-1887.
Score: 0.018
-
BRAF-V600E-mutated Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis with response to BRAF inhibitor. Blood Adv. 2019 06 25; 3(12):1848-1853.
Score: 0.013
-
Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017 12 21; 130(25):2728-2738.
Score: 0.011
-
A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer. 2017 Sep 01; 123(17):3229-3240.
Score: 0.011
-
A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2017 05; 64(5).
Score: 0.011
-
Up-front therapy for LCH: is it time to test an alternative to vinblastine/prednisone? Br J Haematol. 2015 Apr; 169(2):299-301.
Score: 0.009
-
BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014 Apr 07; 211(4):669-83.
Score: 0.009
-
Reactivations in multisystem Langerhans cell histiocytosis: data of the international LCH registry. J Pediatr. 2008 Nov; 153(5):700-5, 705.e1-2.
Score: 0.006
-
Hemophagocytic syndrome after Kawasaki disease. Pediatr Infect Dis J. 2003 Jul; 22(7):663-6.
Score: 0.004